Summary: Hardy Diagnostics has partnered with Gradientech to exclusively distribute the FDA-classified breakthrough QuickMIC system, which aims to improve sepsis care by enabling faster, more accurate antibiotic treatment decisions.
Takeaways:
- Rapid Sepsis Treatment Support: The QuickMIC system provides timely antibiotic sensitivity testing, helping clinicians make faster decisions for treating life-threatening sepsis cases.
- Golden Hour Focus: Recognizing sepsis’s urgency, the device aligns with standards to treat sepsis within an hour, potentially reducing hospital readmissions and improving survival rates.
- U.S. Expansion Through Hardy Diagnostics: Already used in European hospitals, QuickMIC is undergoing U.S. clinical studies and will be distributed across North America by Hardy Diagnostics, leveraging their expertise in clinical microbiology.
Hardy Diagnostics entered into an exclusive partnership with the Swedish-based company Gradientech to distribute its FDA-classified breakthrough device, the QuickMIC.
Support for Sepsis Patients
The QuickMIC results contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Sepsis is a serious condition and a leading cause of death in hospitals.
Each year, according to the Centers for Disease Control and Prevention, at least 1.7 million adults in the U.S. develop sepsis, and at least 250,000 die as a result. Sepsis is also the main reason why people are readmitted to the hospital. The National Institute for Health and Care Excellence urges hospital staff to treat people with life-threatening sepsis within one hour of diagnosis. In clinical practice, this is often referred to as the “golden hour.”
“We are confident that the QuickMIC system will soon become the standard in the hospital laboratory and will be ultimately responsible for saving many lives,” says Jay Hardy, president and founder of Hardy Diagnostics.
Further reading: Sepsis Test Shows the Value of Rapid Diagnosis
About the QuickMIC System
The QuickMIC system is currently undergoing 510(k) clinical studies at two well-renowned hospitals in the United States. The QuickMIC system is already available and in use at many hospitals in Europe.
“As the exclusive distributor of QuickMIC in the US and Canada, Hardy Diagnostics will leverage its extensive network and knowledge of the clinical microbiology landscape to bring this innovative AST system to healthcare providers across North America,” says Sara Thorslund, CEO of Gradientech. “I believe few others can match Hardy Diagnostics’ expertise in the US clinical microbiology market. Our two companies also share a common vision and place great value on our teams, ensuring a good partnership.”
Featured image: QuickMIC system. Photo: Hardy Diagnostics
